HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib
2018 · Annals of Oncology · 215 citations
https://doi.org/10.1093/annonc/mdy542
C
Caicun Zhou
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
226
Papers
7.9K
Citations
42
h-index
103
i10-index
Caicun Zhou is an academic researcher from Tongji University. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Cancer Immunotherapy and Biomarkers & Lung Cancer Research Studies. The author has an h-index of 42, co-authored 193 publications.
ORCID: 0000-0002-1072-9941Papers by this author
worksConsensus for HER2 alterations testing in non-small-cell lung cancer
2022 · ESMO Open · 105 citations
https://doi.org/10.1016/j.esmoop.2022.100395
Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysis
2015 · Oncotarget · 66 citations
https://doi.org/10.18632/oncotarget.6612
Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer
2024 · Cancer Cell · 66 citations
https://doi.org/10.1016/j.ccell.2024.06.001
Impact of lymphadenectomy extent on immunotherapy efficacy in postresectional recurred non-small cell lung cancer: a multi-institutional retrospective cohort study
2023 · International Journal of Surgery · 64 citations
https://doi.org/10.1097/js9.0000000000000774
On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial
2022 · Molecular Cancer · 53 citations
https://doi.org/10.1186/s12943-021-01479-4
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat